PURPOSE: To evaluate a treatment for breast cancer and to demonstrate the safe use of iridium-192 high-dose-rate (HDR) implantations. MATERIALS AND METHODS: In December 1984, the authors began to use HDR Ir-192 brachytherapy to deliver an interstitial boost to the primary site in conservative breast cancer treatment. By December 1989, 212 patients with 216 tumors were treated with external-beam irradiation of 45-50 Gy to the whole breast, which was followed by an interstitial 10-Gy boost. Median follow-up was 62 months (range, 36-101 months). RESULTS: Ten patients (10 of 216 breasts, 4.6%) developed local tumor recurrences, and 36 (17.0%) had distant metastases. At 5 years, overall survival was 88%, local tumor control was 96%, and disease-free survival was 81%. There were no serious complications. CONCLUSION: The use of an HDR source as a boost to the primary tumor site after external-beam radiation therapy with a dose of 10 Gy in one fraction is a safe procedure and does not negatively affect cosmetic appearance.
PURPOSE: To evaluate a treatment for breast cancer and to demonstrate the safe use of iridium-192 high-dose-rate (HDR) implantations. MATERIALS AND METHODS: In December 1984, the authors began to use HDR Ir-192 brachytherapy to deliver an interstitial boost to the primary site in conservative breast cancer treatment. By December 1989, 212 patients with 216 tumors were treated with external-beam irradiation of 45-50 Gy to the whole breast, which was followed by an interstitial 10-Gy boost. Median follow-up was 62 months (range, 36-101 months). RESULTS: Ten patients (10 of 216 breasts, 4.6%) developed local tumor recurrences, and 36 (17.0%) had distant metastases. At 5 years, overall survival was 88%, local tumor control was 96%, and disease-free survival was 81%. There were no serious complications. CONCLUSION: The use of an HDR source as a boost to the primary tumor site after external-beam radiation therapy with a dose of 10 Gy in one fraction is a safe procedure and does not negatively affect cosmetic appearance.
Authors: José Luis Guinot; M Isabel Tortajada; María Carrascosa; Vicente Crispín; Ana Otero; Belén Ríos; Eleonor Rivin; Miguel Santos; Pablo Soler; Leoncio Arribas Journal: Clin Transl Oncol Date: 2012-02 Impact factor: 3.405
Authors: Aurora Rodríguez Pérez; Maria Concepción López Carrizosa; Pilar Maria Samper Ots; José Fermín Pérez-Regadera Gómez; José Zapatero Ortuño; Juan de Dios Sáez Garrido; Manuel Joaquín Martín de Miguel Journal: Clin Transl Oncol Date: 2012-09-14 Impact factor: 3.405
Authors: Aurora Rodríguez Pérez; Pilar María Samper Ots; María Concepción López Carrizosa; José Fermín Pérez-Regadera Gómez; José Zapatero Ortuño; Juan de Dios Sáez Garrido; Manuel Joaquín Martín de Miguel Journal: Clin Transl Oncol Date: 2012-05 Impact factor: 3.405
Authors: Inmaculada Beato Tortajada; Jose Luis Guinot Rodríguez; Leoncio Arribas Alpuente; Manuel Aguayo Martos; María Carrascosa Pérez; Maribel Tortajada Azcutia; Pedro Pablo Escolar Pérez; María Maroñas Martín; Marisa Chust Vicente; José Luis Mengual Cloquell; Carmen Pesudo Ayet; Manuel Casaña Giner Journal: Clin Transl Oncol Date: 2005-10 Impact factor: 3.405
Authors: Krystyna Serkies; Zofia Tarnawska; Andrzej Blukis; Andrzej Badzio; Janusz Jaskiewicz; Jacek Jassem Journal: J Contemp Brachytherapy Date: 2009-03-23